Printer Friendly

Elanco Animal Health wins US FDA approval for Credelio to treat and protect dogs against ticks and fleas.

M2 EQUITYBITES-January 23, 2018-Elanco Animal Health wins US FDA approval for Credelio to treat and protect dogs against ticks and fleas


Elanco Animal Health reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for Credelio (lotilaner) for the treatment and protection of dogs against ticks and fleas.

The company said Credelio is a new monthly oral tick and flea treatment that is easy on dogs, but tough on ticks and fleas. This new tick and flea option for dogs contains the patented active ingredient lotilaner, which targets the nervous system receptors of ticks and fleas, not dogs.1

According to the company, Credelio is a small, tasty chewable tablet approved for puppies and dogs eight weeks of age and older and 4.4 pounds and greater. It protects against ticks: lone star tick (Amblyomma americanum), American dog tick (Dermacentor variabilis), black-legged tick (Ixodes scapularis) and brown dog tick (Rhipicephalus sanguineus), as well as fleas (Ctenocephalides felis).

Under the company's field study, 100% of Credelio tablets were administered successfully and dogs accepted 94% of them when offered by hand in an empty bowl, or with food. It was well accepted by a broad range of dog breeds, including Chihuahuas and Yorkshire terriers.

In conjunction with the company's clinical studies, Credelio killed 100% of fleas within 12 hours in four hours for the entire month, providing rapid relief from existing ticks. Its sustained speed-of-kill throughout the dosing period provides protection from newly-acquired ticks. It is absorbed rapidly and achieves peak plasma levels quickly. Its active ingredient--lotilaner--circulates in the dog's blood stream, targeting the receptors of ticks and fleas when they bite the dog.

Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries and is a division of Eli Lilly and Company (NYSE:LLY).

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 23, 2018
Previous Article:Cherry's bondholders approve proposed amendments of the terms for its EUR200,000m bond loan.
Next Article:Water Street & medical partner awarded US FDA approval for Bivalirudin in first frozen premixed ready-to-use formulation presentation.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |